Arcellx, Inc.: 5%+ holders

As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Arcellx, Inc. The largest reported stake is Gilead Sciences, Inc.'s, at 100%. 21 filings are on record since August 14, 2025 (Schedule 13D/A, April 28, 2026).

New Enterprise Associates 15, L.P. also filed stake reports on 1 other company ↓

Sell to companies like Arcellx, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-05-15 · Holder: Vestal Point Capital, LP · Percent: 0% · SCHEDULE 13G/A
• Filed 2026-04-30 · Holder: New Enterprise Associates 15, L.P. · Percent: 0% · SCHEDULE 13D/A
• Event date 2026-04-28 · Holder: Gilead Sciences, Inc. · Percent: 100% · Shares: 100 · SCHEDULE 13D/A
• Event date 2026-04-28 · Holder: Rami Elghandour · Percent: 0% · Shares: 0 · SCHEDULE 13D/A

Arcellx, Inc. has 21 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Arcellx, Inc. and the warning signs.

See Arcellx, Inc.'s free Snapshot Watch Arcellx, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Arcellx, Inc. and the records around it.

Arcellx, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• New Enterprise Associates 15, L.P. also filed stake reports on 1 other company: Senti Biosciences, Inc. (Mar 2026)
• Gilead Sciences, Inc. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), Arcus Biosciences, Inc. (Aug 2026), ASSEMBLY BIOSCIENCES, INC. (May 2026)
• Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)

Want the whole picture on Arcellx, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Arcellx, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Arcellx, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   22 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Arcellx, Inc. by CUSIP 03940C100 and gives its principal executive office as 800 Bridge Parkway, Redwood City, CA 94065 (SCHEDULE 13G/A, 2026-08-14).

Purpose of Transaction (Item 4)

New Enterprise Associates 15, L.P.

As previously disclosed by the Issuer on February 23, 2026, the Issuer entered into an Agreement and Plan of Merger, dated as of February 22, 2026 (the "Merger Agreement"), with Gilead Sciences, Inc., a Delaware corporation ("Parent") and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on April 28, 2026, Purchaser completed a tender offer (the "Offer") to purchase all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (i) $115.00 per share of Common Stock, net to the seller in cash, without interest and subject to any applicable withholding tax, and (ii) one contractual contingent value right (each, a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR, in cash, without interest and subject to any applicable withholding tax, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement. Pursuant to the Support Agreements, NEA 15 tendered all of its shares of Common Stock in the Offer, which shares were accepted for payment by Purchaser. Following the consummation of the Offer, on April 28, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent. The foregoing descriptions of the Merger Agreement and the Support Agreements …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-30; the filing has the rest

Gilead Sciences, Inc.

Item 4 of the Original Schedule 13D is amended to include the following at the end thereof: "As previously disclosed, Gilead, Purchaser and Arcellx entered into the Merger Agreement pursuant to which Purchaser commenced the Offer on March 6, 2026. The Offer expired at 5:00 p.m., Eastern Time, on April 27, 2026. Computershare Trust Company N.A., the depositary and paying agent for the Offer, advised Gilead that, as of the expiration of the Offer, 38,795,604 Shares had been validly tendered and not validly withdrawn pursuant to the Offer, representing, together with Shares already owned by Gilead, approximately 77.2% of the Shares outstanding as of the expiration of the Offer. Following consummation of the Offer, on April 28, 2026, Gilead completed its acquisition of Arcellx through the merger of Purchaser with and into Arcellx, and without a meeting of the stockholders of Arcellx in accordance with Section 251(h) of the DGCL, with Arcellx surviving such Merger as a wholly owned subsidiary of Gilead. In connection with the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (other than (i) Shares owned immediately prior to the effective time of the Merger by Arcellx (including those held in Arcellx's treasury), (ii) Shares owned both as of the commencement of the Offer and immediately prior to the effective time of the Merger by Gilead, Purchaser or any other direct or indirect wholly owned subsidiary of Gilead, (iii) Shares …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-28; the filing has the rest

Rami Elghandour

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: Tender Offer and Closing of the Merger As previously disclosed by the Issuer on February 23, 2026, the Issuer entered into an Agreement and Plan of Merger, dated as of February 22, 2026 (the "Merger Agreement"), with Gilead Sciences, Inc., a Delaware corporation ("Parent") and Ravens Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on April 28, 2026, Purchaser completed a tender offer to purchase (the "Offer") all of the Issuer's outstanding common stock in exchange for (x) $115.00 per share, net to the seller in cash, without interest and subject to any required withholding of taxes (the "Closing Amount"), and (y) one contractual contingent value right per share (each, a "CVR," and each CVR together with the Closing Amount, the "Merger Consideration"), which represents the right to receive one contingent milestone payment of $5.00 per CVR, in cash, without interest and subject to any required withholding of taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement. Following the consummation of the Offer, on April 28, 2026 (the "Closing Date"), Purchaser merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-28; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Arcellx, Inc.

Who owns Arcellx, Inc.?

On this page, one holder's latest ownership filing reports 5% or more of Arcellx, Inc.: Gilead Sciences, Inc. (100%, Schedule 13D/A, filed 2026-04-28).

When did Gilead Sciences, Inc. buy into Arcellx, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Gilead Sciences, Inc. on this page is the Schedule 13D, filed 2026-02-23, reporting 11.5%; its latest, Schedule 13D/A filed 2026-04-28, reports 100%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Arcellx, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Arcellx, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Arcellx, Inc. is mentioned again
• Find former Arcellx, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes